Invesco Pharmaceuticals ETF news

The ETF shows solid performance gains (24.96% YTD, 41.74% 1-year) and reasonable expense ratio (0.57%), but carries higher risk with concentrated holdings (32 stocks, top 10 = 49.52% of assets) and elevated volatility (16.02% standard deviation). Zacks ETF Rank of 3 (Hold) indicates it's a viable option but not a strong buy.

Presented as a solid alternative with strengths including higher dividend yield (0.8%), lower volatility (beta 0.45), superior 5-year returns, and broader pharmaceutical diversification; however, not selected as the recommended choice despite better historical performance.

Better long-term returns (41.1% 1-year return), lower maximum drawdown (17.5%), larger AUM ($512.6M) providing better liquidity, and recommended as the better buy despite higher expense ratio.

PJP is recommended as the better buy for 2026 due to consistent outperformance over 3-year (17.3%), 5-year (9.1%), and 10-year (7.5%) periods, with exceptional 1-year returns of 45.10%. The concentrated approach in 29 pharmaceutical stocks has proven effective despite higher expense ratio.

PJP is recommended as the better choice, demonstrating superior performance with 44.90% 1-year returns, outperforming IXJ across most timeframes (YTD, 3-year, 5-year), and achieving this with a smaller maximum drawdown despite a slightly higher expense ratio.

Recommended as the better buy with superior 5-year returns ($1,563 vs $1,480), lower maximum drawdown (17.50% vs 29.90%), dividend yield of 0.90%, and lower volatility (beta 0.45). Benefits from GLP-1 boom exposure through holdings like Eli Lilly.

Demonstrates strong 1-year returns (49.90%) benefiting from U.S. pharma sector momentum, but offset by higher expense ratio (0.57%), lower dividend yield (0.90%), smaller AUM ($358.7M), and underperformance over 5 years. Suitable for specific investor profiles seeking U.S.-only exposure.